Want to join the conversation?
In February 2015, $REGN and Sanofi entered into an amended ZALTRAP agreement under which Sanofi is solely responsible for the development and commercialization of ZALTRAP Injection for Intravenous Infusion for cancer indications worldwide. Sanofi bears the cost of all development & commercialization activities and reimburses $REGN for its costs.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.